In this program project, we propose a Personalized Medicine approach to the study of advanced lung disease. We hypothesize that sub-phenotypes of common diseases, including pulmonary arterial hypertension (PAH), have a profound influence on outcome and responsiveness to therapy. The overarching translatlonal goal of this program is to define common mechanistic and therapeutic pathways for PAH in the context of major lung and systemic diseases, such as COPD and HIV. Our proposed three major projects and two cores are designed to integrate and synergize fundamental translatlonal research addressing major current and high impact problems in the PAH and advanced lung disease field. Because translational medicine requires a bench-to-bedside-to-bench integrated approach, we developed a full translatlonal continuum from preclinical models in three species, including a novel primate PAH model, screening and clinical drug development programs, human hemodynamic phenomic assessments, genetics, and clinical epidemiological trials focused initially on two major disease targets, COPD and HIV, which represent two prototypic models of the pulmonary hypertension sub-phenotype. Our three proposed projects and cores all individually and collaboratively align across this translational spectrum, driving an effort to understand fundamental mechanisms of disease, identify small molecule therapeutic agents, develop screening biomarkers for vascular sub-phenotypes of lung disease, and to set the stage for phase II and III clinical trials. Successes in the first five years of this project are expected to develop into phase ll-lll clinical trials and extension to other advanced lung diseases, such as interstitial lung disease and obstructive sleep apnea, in years 6 to 10. Project 1: Pulmonary hypertension in COPD: Genetic and Environmental Determinants Project 2: ROS signaling and NOS uncoupling in pulmonary vascular disease Project 3: Pulmonary vascular-targeted NO therapeutic strategies Core A: Administrative core Core B: Pre-Clinical Models of PAH Core C: Translational Vascular Phenomics, Genomics and Epidemiology Core

Public Health Relevance

Pulmonary vascular disease is a relatively understudied, but Important sub-phenotype in COPD, HIV, IPF, and OSA that is associated with excessive morbidity and mortality, and presents unique therapeutic opportunities.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL103455-02
Application #
8268999
Study Section
Special Emphasis Panel (ZHL1-CSR-A (M1))
Program Officer
Moore, Timothy M
Project Start
2011-06-01
Project End
2016-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
2
Fiscal Year
2012
Total Cost
$2,556,023
Indirect Cost
$868,879
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Farkas, Daniela; Thompson, A A Roger; Bhagwani, Aneel R et al. (2018) Toll-like Receptor 3 is a Therapeutic Target for Pulmonary Hypertension. Am J Respir Crit Care Med :
Goncharov, Dmitry A; Goncharova, Elena A; Tofovic, Stevan P et al. (2018) Metformin Therapy for Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction versus Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 198:681-684
Rafikova, Olga; Williams, Elissa R; McBride, Matthew L et al. (2018) Hemolysis-induced Lung Vascular Leakage Contributes to the Development of Pulmonary Hypertension. Am J Respir Cell Mol Biol 59:334-345
Hensley, Matthew K; Levine, Andrea; Gladwin, Mark T et al. (2018) Emerging therapeutics in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 314:L769-L781
Potoka, Karin P; Wood, Katherine C; Baust, Jeffrey J et al. (2018) Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease. Am J Respir Cell Mol Biol 58:636-647
Simon, Marc A; Schnatz, Rick G; Romeo, Jared D et al. (2018) Bedside Ultrasound Assessment of Jugular Venous Compliance as a Potential Point-of-Care Method to Predict Acute Decompensated Heart Failure 30-Day Readmission. J Am Heart Assoc 7:e008184
Levine, Andrea R; Simon, Marc A; Gladwin, Mark T (2018) Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction. Trends Cardiovasc Med :
Khoo, Nicholas K H; Li, Lihua; Salvatore, Sonia R et al. (2018) Electrophilic fatty acid nitroalkenes regulate Nrf2 and NF-?B signaling:A medicinal chemistry investigation of structure-function relationships. Sci Rep 8:2295
Woodcock, Chen-Shan Chen; Huang, Yi; Woodcock, Steven R et al. (2018) Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth. J Biol Chem 293:1120-1137
Raghu, Vineet K; Ramsey, Joseph D; Morris, Alison et al. (2018) Comparison of strategies for scalable causal discovery of latent variable models from mixed data. Int J Data Sci Anal 6:33-45

Showing the most recent 10 out of 182 publications